Page 620 - Read Online

Page 10 of 11 Puoti. Hepatoma Res 2018;4:57 I http://dx.doi.org/10.20517/2394-5079.2018.67

3. Ružić M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brkić S, Abenavoli L. Hepatitis C virus-induced hepatocellular carcinoma: a narrative
review. Panminerva Med 2018; doi: 10.23736/S0031-0808.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2011;53:1020-2.
5. Cabrera R, Nelson DR. The management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31:461-76.
6. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of
compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10.
7. Chacko S, Samanta S. Hepatocellular carcinoma: a life-threatening disease. Biomed Pharmacother 2016;84:1679-88.
8. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD Guidelines for the
treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.
9. Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio
F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two
decades in Italy. J Hepatol 2012;56:397-405.
10. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
11. Ioannou G, Splan M, Weiss N, McDonald G, Beretta L, Lee S. Incidence and predictors of hepatocellular carcinoma in patients with
cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-45.
12. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterl ng RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovs.ky HL, Dienstag
JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in
hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
13. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T. Prospective risk assessment for hepatocellular carcinoma development in
patients with chronic hepatitis C by transient elastography. Hepatology 2009;49:1954-61.
14. Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related
hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53:885-94.
15. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S303-9.
16. Deugnier YM, Guyader D, Crantock L, Lopez JM, Turlin B, Yaouanq J. Primary liver cancer in genetic hemochromatosis: a clinical,
pathological, and pathogenetic study of 54 cases. Gastroenterology 1993;104:228-34.
17. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. REVEAL-HBV Study Group. Risk
of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
18. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and
hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-72.
19. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk evaluation of viral load elevation and associated liver disease/cancer-In HBV
(the REVEAL-HBV) study group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology
2006;130:678-86.
20. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N,
Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL,
Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral
therapy. J Hepatol 2016;64:800-6.
21. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular
carcinoma. Pathol Biol 2010;58:273-7.
22. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thorav F. The burden of liver disease in Europe: a review of available
epidemiological data. J Hepatol 2013;58:593-608.
23. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S,
Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence
and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7.
24. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related
morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-8.
25. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol 2018;6:79-
84.
26. Puoti C, Bellis L, Martellino F, Durola L, Spilabotti L, Dell’Unto O. Occurrence of hepatocellular carcinoma in an apparently ‘healthy’
HCV patient. Eur J Gastroenterol Hepatol 2005;17:1263-4.
27. Puoti C, Lanzetta G, Scotti E. Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection. J
Gastrointestin Liver Dis 2016;25:408-9.
28. Puoti C, Stati T, Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal
aminotransferase levels. Liver 1999;19:104-9.
29. Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, Cabibbo G, Rossi S, Calvaruso V, Aghemo A, Giacomelli L, Craxì
A, Colombo M, Maisonneuve P. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related
cirrhosis who attained sustained virological response. Liver Int 2017;37:1526-34.
30. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
31. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim
F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S,
Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis
C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS
CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications.